Jordan S. Kesner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jordan S. Kesner has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Aditi Trehan
Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, USA
2 shared publications- Alexis O. Aparicio
Department of Medicine, Department of Systems Biology, Columbia University Medical Center, New York, USA
2 shared publications Michael R. Murphy
Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, USA
2 shared publications- Xuebing Wu
Department of Medicine and Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA
2 shared publications Yang Guo
Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, USA
2 shared publications- Ziheng Chen
Carnegie Mellon University
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (9) , 2226-2239
Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer
- 26 August 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (9) , 2226-2239
Open AccessDevelopmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer
- Top Cited Papers
- 12 April 2023
- Published by Springer Nature in Nature
- Vol. 617 (7960) , 395-402
Noncoding translation mitigation
Translation is pervasive outside of canonical coding regions, occurring in long noncoding RNAs, canonical untranslated regions and introns1,2,3,4, especially in ageing4,5,6, neurodegeneration5,7 and cancer8,9,10. Notably, the majority of tumour-specific antigens are results of noncoding translation11,12,13. Although the resulting polypeptides are often nonfunctional, translation of noncoding regions is nonetheless necessary for the birth of new coding sequences14,15. The mechanisms underlying the surveillance of translation in diverse noncoding regions and how escaped polypeptides evolve new functions remain unclear10,16,17,18,19. Functional polypeptides derived from annotated noncoding sequences often localize to membranes20,21. Here we integrate massively parallel analyses of more than 10,000 human genomic sequences and millions of random sequences with genome-wide CRISPR screens, accompanied by in-depth genetic and biochemical characterizations. Our results show that the intrinsic nucleotide bias in the noncoding genome and in the genetic code frequently results in polypeptides with a hydrophobic C-terminal tail, which is captured by the ribosome-associated BAG6 membrane protein triage complex for either proteasomal degradation or membrane targeting. By contrast, canonical proteins have evolved to deplete C-terminal hydrophobic residues. Our results reveal a fail-safe mechanism for the surveillance of unwanted translation from diverse noncoding regions and suggest a possible biochemical route for the preferential membrane localization of newly evolved proteins.
- 12 April 2023
- Published by Springer Nature in Nature
- Vol. 617 (7960) , 395-402
Top Cited PapersNoncoding translation mitigation
Translation is pervasive outside of canonical coding regions, occurring in long noncoding RNAs, canonical untranslated regions and introns1,2,3,4, especially in ageing4,5,6, neurodegeneration5,7 and cancer8,9,10. Notably, the majority of tumour-specific antigens are results of noncoding translation11,12,13. Although the resulting polypeptides are often nonfunctional, translation of noncoding regions is nonetheless necessary for the birth of new coding sequences14,15. The mechanisms underlying the surveillance of translation in diverse noncoding regions and how escaped polypeptides evolve new functions remain unclear10,16,17,18,19. Functional polypeptides derived from annotated noncoding sequences often localize to membranes20,21. Here we integrate massively parallel analyses of more than 10,000 human genomic sequences and millions of random sequences with genome-wide CRISPR screens, accompanied by in-depth genetic and biochemical characterizations. Our results show that the intrinsic nucleotide bias in the noncoding genome and in the genetic code frequently results in polypeptides with a hydrophobic C-terminal tail, which is captured by the ribosome-associated BAG6 membrane protein triage complex for either proteasomal degradation or membrane targeting. By contrast, canonical proteins have evolved to deplete C-terminal hydrophobic residues. Our results reveal a fail-safe mechanism for the surveillance of unwanted translation from diverse noncoding regions and suggest a possible biochemical route for the preferential membrane localization of newly evolved proteins.
- Open Access
- 28 March 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-8
Collateral activity of the CRISPR/RfxCas13d system in human cells
CRISPR/Cas13 systems are increasingly used for programmable targeting of RNAs. While Cas13 nucleases are capable of degrading both target RNAs and bystander RNAs in vitro and in bacteria, initial studies fail to detect collateral degradation of non-target RNAs in eukaryotic cells. Here we show that RfxCas13d, also known as CasRx, a widely used Cas13 system, can cause collateral transcriptome destruction when targeting abundant reporter RNA and endogenous RNAs, resulting in proliferation defect in target cells. While these results call for caution of using RfxCas13d for targeted RNA knockdown, we demonstrated that the collateral activity can be harnessed for selective depletion of a specific cell population defined by a marker RNA in an in vitro setting.
- 28 March 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-8
Open AccessCollateral activity of the CRISPR/RfxCas13d system in human cells
CRISPR/Cas13 systems are increasingly used for programmable targeting of RNAs. While Cas13 nucleases are capable of degrading both target RNAs and bystander RNAs in vitro and in bacteria, initial studies fail to detect collateral degradation of non-target RNAs in eukaryotic cells. Here we show that RfxCas13d, also known as CasRx, a widely used Cas13 system, can cause collateral transcriptome destruction when targeting abundant reporter RNA and endogenous RNAs, resulting in proliferation defect in target cells. While these results call for caution of using RfxCas13d for targeted RNA knockdown, we demonstrated that the collateral activity can be harnessed for selective depletion of a specific cell population defined by a marker RNA in an in vitro setting.